DHA + ARA: Why They Are Known As The Golden Pair? What Are The Limitations Of DHA Supplementation Alone?

In the fields of infant and young child nutrition, maternal and infant food, and dietary supplements, DHA is widely known as "brain gold". It serves as a core nutritional indicator for parents selecting products and buyers sourcing supplies. Yet many people wonder: why do premium infant formula powders and specialized infant nutritional supplements almost always feature a DHA+ARA combination, rather than DHA alone? What exactly makes the industry-recognized "golden pair of DHA and ARA" so valuable? What tangible downsides come with supplementing DHA on its own? Written in plain, accessible language, this article addresses both ordinary parents' childcare needs and buyers' product-selection criteria, thoroughly unpacking their synergistic benefits and the limitations of single-nutrient supplementation.

First, the key takeaway: DHA and ARA are not merely added together. They function as an interdependent, complementary pair whose synergistic effects cannot be replaced by either nutrient alone - this is the fundamental reason behind the "golden pair" title. Breast milk, the gold standard for infant nutrition, naturally contains both DHA and ARA at a ratio ranging from 1:1 to 1:2, with the optimal golden ratio around 1:1.7. This proportion, shaped by millions of years of natural evolution, acts as the reference benchmark for all infant formula foods and nutritional supplements.

When it comes to functional roles, DHA and ARA have distinct but coordinated responsibilities, jointly supporting infants' visual and brain development, physical growth and immune regulation. Most people only know DHA benefits vision and brain health, but its core role is forming the foundational structure of the nervous and visual systems. DHA is a key structural component of the cerebral cortex and retina. It enhances cell membrane fluidity, accelerates nerve signal transmission, and directly supports infants' visual development, cognitive advancement and attention span - acting as the "building framework" for nervous system development.

ARA, by contrast, compensates for DHA's functional gaps and serves as the critical enabler for nutritional benefits to take effect. ARA, or arachidonic acid, is abundant in the human brain, liver and immune cells. Its primary functions include refining cellular structures, regulating physiological signaling, facilitating growth and strengthening immune responses. If DHA builds the structural framework of the brain and visual system, ARA is the construction material and power system that refines details, reinforces structures and activates physiological functions. Clinical research confirms ARA accounts for 40%–50% of fatty acids in the cerebral cortex, far exceeding DHA's 20% share, which proves ARA's irreplaceable core status in brain development.

The paired combination delivers a 1+1>2 nutritional outcome: DHA enables fast nerve signaling for quicker responses and sharper vision; ARA consolidates nerve cell architecture, stimulates brain cell proliferation and differentiation, while supporting skeletal growth and immune maturation. Together, they support comprehensive intellectual and visual development and avoid developmental shortfalls caused by missing one nutrient - this is the core value of the golden pair.

Compared with well-balanced combined supplementation, DHA-only supplementation carries clear limitations and may even trigger adverse metabolic effects, which is why the industry does not recommend standalone DHA intake.

First, isolated DHA supplementation suppresses endogenous ARA synthesis and creates nutritional imbalance. DHA and ARA share the same metabolic enzymes in the human body. Infants only possess 10%–30% of the enzyme activity seen in adults, leaving them with inherently limited metabolic capacity. High-dose DHA supplementation alone competes for these limited metabolic resources, inhibiting ARA synthesis and bioavailability and resulting in insufficient ARA levels. This seesaw-style imbalance undermines the benefits of DHA and slows visual and neurodevelopment.

Second, DHA-only supplementation cannot support holistic growth, raising risks of developmental lags. DHA focuses mainly on neural and visual development and does not participate in core physiological processes governing somatic growth and immune modulation. Without ARA, infants may exhibit slower weight and physical growth, weaker immune defenses and greater susceptibility to colds and allergies. Multiple pediatric controlled trials show infants receiving only DHA score up to 7 points lower on mental development and physical growth metrics at 18 months than infants receiving balanced DHA+ARA.

Third, standalone DHA leads to incomplete neural maturation, drastically reducing nutritional returns. Fully realized brain development requires DHA to lay nerve conduction pathways and ARA to refine synaptic connections and modulate cellular signaling. Without ARA, the neural framework built by DHA cannot become functionally active, creating a scenario of "structure without function". This manifests as slower cognitive responses and weaker learning adaptability, failing to deliver the intended cognitive benefits. ARA deficiency also destabilizes retinal cells, preventing optimal visual maturation.

Fourth, from a long-term nutritional perspective, DHA-only supplementation conflicts with innate human nutritional patterns. DHA never occurs in isolation in breast milk; it naturally coexists with ARA at a balanced ratio, a nutritional pattern evolved to match infant physiology. Breaking this pattern with long-term DHA monosupplementation can disrupt long-chain fatty acid metabolism, compromising not only infant-stage development but also potentially raising risks for adverse immune and metabolic outcomes later in life.

For consumers, understanding this principle helps avoid the common misconception of prioritizing DHA content above all else. Many parents blindly chase higher DHA levels while ignoring ARA ratios, spending money without achieving desired nutritional outcomes. High-quality supplementation hinges not on maximizing DHA dosage, but on a balanced, synergistic DHA-to-ARA ratio.

For procurement specialists, distributors and brand owners, this is core logic for product selection and formulation upgrading. Low-end nutritional products on the market often add DHA alone; they carry attractive marketing claims and seemingly favorable pricing, yet contain incomplete nutrition. End-users commonly report poor perceived effects, leading to low repurchase rates and weak brand reputation. Products formulated with the golden DHA+ARA ratio (1:1 ~ 1:2) align with breast milk nutritional benchmarks, deliver more complete nutrition and suit infants across developmental stages. They fit prevailing consumer trends, mitigate formulation defects, and boost product competitiveness and user satisfaction.

In summary, DHA and ARA earn the title of infant nutrition's golden pair not from simple addition, but through functional complementarity, metabolic synergy, natural physiological compatibility and amplified benefits. The biggest limitation of DHA-only supplementation is that it disrupts innate nutritional equilibrium: it greatly diminishes brain and vision benefits and may delay growth and immune maturation. Whether caregivers are selecting supplements for infants or industry stakeholders are planning product portfolios, prioritizing products with a scientifically balanced DHA+ARA ratio (rather than single-nutrient DHA) delivers comprehensive, efficient nutritional support for healthy infant development.

References

[1] Yin Shi'an. Human Milk Composition: Occurrence Forms, Contents, Functions and Detection Methods [M]. Beijing: Chemical Industry Press, 2016.

[2] Yang Yuexin, Li Ning. Guidelines for the Application of Nutritional Functional Ingredients [M]. Beijing: Peking University Medical Press, 2011.

[3] Chinese Nutrition Society. Chinese Dietary Reference Intakes (2023 Edition) [M]. Beijing: People's Medical Publishing House, 2023.

[4] Hadley K B, Ryan A S, Forsyth S, et al. The essentiality of arachidonic acid in infant development [J]. Nutrients,2016,8 (4):216.

[5] Birch E E, Garfield S, Hoffman D R, et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants [J]. Developmental Medicine and Child Neurology,2000,42 (3):174-181.

[6] Carlson S E. Docosahexaenoic acid and arachidonic acid in infant development [J]. Seminars in Neonatology,2001,6 (1):17-29.

[7] Expert Group on DHA Supplementation for Chinese Pregnant, Lactating Women and Infants. Expert Consensus on DHA Supplementation for Pregnant, Lactating Women and Infants in China [J]. Chinese Journal of Reproductive Health, 2015,26 (2):101-105.

[8] Koletzko B, et al. Current information and Asian perspectives on long-chain polyunsaturated fatty acids in pregnancy, lactation, and infancy [J]. Annals of Nutrition and Metabolism,2014,65:49-80.